Teen Use of ADHD Meds Up Sharply


By Nancy Walsh, Staff Writer, MedPage Today
Published: September 29, 2011
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and

Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

Methylphenidate (Ritalin) 10mg Pill (Ciba/Nova...                               Image via WikipediaThe use of stimulant medications among children with attention deficit hyperactivity disorder (ADHD) continues to rise, particularly among adolescents, a nationally representative survey showed.

In 2008, these medications were used by 3.5% (95% CI 3.0 to 4.1) of children ages 18 and younger compared with 2.4% (95% CI 1.8 to 2.9) in 1996, according to Samuel H. Zuvekas, PhD, of the Agency for Healthcare Research and Quality in Rockville, Md., and Benedetto Vitiello, MD, of the National Institute of Mental Health in Bethesda, Md.

But among those ages 13 to 18, the rate of use increased by 6.5% annually, rising from 2.3% (95% CI 1.5 to 3.1) in 1996 and reaching 5% (95% CI 3.9 to 6.1) by 2008 (P<0.001), the researchers reported online in the American Journal of Psychiatry.

Action Points  


  • Explain that the use of stimulant medications among children with attention deficit hyperactivity disorder (ADHD) continues to rise, particularly among adolescents.
  • Note that consistent with the gender predominance of ADHD, three times as many boys as girls were treated with stimulants.
Some 9% of children ages 6 to 17 at some time have been diagnosed as having ADHD. Prescribing of stimulant medications rose sharply in the 1990s, and in the subsequent decade numerous new formulations were developed.
“As the market for ADHD medications has expanded, concerns have been raised about the possible misuse and abuse of stimulants, especially because the increase in ADHD diagnoses has been most marked in adolescents,” the researchers wrote.
To examine the patterns of use of drugs such as methylphenidate and amphetamines among young people, Zuvekas and Vitiello analyzed data from the Medical Expenditure Panel Survey, an ongoing report that follows trends in the treatment of psychiatric disorders.
They found that approximately 2.8 million children were using stimulants in 2008, a number that had risen by 3.4% each year since 1996.
The rate of use was highest among children ages 6 to 12, and that rate has held fairly steady over time — 4.2% (95% CI 3.2 to 5.2) were treated with stimulant medications in 1996, while 5.1% (95% CI 4.1 to 6.1) were on the drugs in 2008.
Children younger than 6 were the least common recipients of stimulant medications. Before 2004, yearly estimates for this age group were 0.3% to 0.4%, but thereafter fell to and remained at 0.1%, which was a significant decrease (t=3.71, P<0.001), according to the researchers.
Although a clinical trial in 2006 demonstrated efficacy for methylphenidate among preschool-age children, it also identified a higher incidence of adverse effects, and the current data showed that, in fact, ADHD medications are little used in the youngest children, Zuvekas and Vitiello pointed out.
Reflecting the gender predominance of ADHD, three times as many boys as girls were treated with stimulants (5.3% versus 1.6%).
Use was highest in whites, being 4.4% in 2008, compared with 3% of African Americans and 2.1% of Hispanics.
And although use was lower in minorities, it had risen notably from 1.9% and 0.7% in 1996 among African Americans and Hispanics, respectively.
This reflects a growing recognition of ADHD among groups that have often been underserved in mental health resources, while also suggesting that cultural barriers remain, according to the researchers.
Rates were low (1.3%) among children lacking health insurance, and those with public insurance were more likely to be on the medications than those with private insurance (OR 1.36, t=2.14, P=0.016).
Geography also influenced use, with 4.6% of children in the Northeast taking stimulants in 2008 compared with 1.6% of those living in the West.
The survey suggested that the majority of children with ADHD actually do not receive stimulant medications.
“This may not be unexpected, since about half of those diagnosed present with only mild symptoms and since other treatments, including psychosocial interventions and nonstimulant medications, are available,” the researchers explained.
Among other medications taken by small numbers of children were clonidine, guanfacine, and atomoxetine (Strattera).
The findings of this study should be interpreted in light of certain limitations, they noted, such as possible recall bias and underestimation of medication use, as well as a lack of validation for diagnoses in the survey.
The authors reported no financial disclosures.

Enhanced by Zemanta

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis


Frontage of Heslington Hall, York, the adminis...Image via Wikipedia

Para los creyentes del Déficit de Atención, y que no se piense que hay sesgo de publicación. Lo que falta es tiempo para escribir. 

Esparza Olcina MJ. Comparación de la eficacia de los estimulantes para el TDAH en niños y
 adolescentes según un metaanálisis. Evid Pediatr. 2011;7:102.
Traducción autorizada de: Centre of Reviews and Dissemination (CRD). Comparing the efficacy 
of stimulants for ADHD in children and adolescents using meta-analysis. University of York
Database of Abstracts of Review of Effects web site (DARE).
 Documento número: 12010003072 [en línea] [fecha de actualización: 2011; 
fecha de consulta: 9-6-2011]. 
Disponible en:

Documento en Castellano
Document in English           

Antipsychotics Increase Adiposity, Insulin Resistance in Children


Source: http://www.familypracticenews.com

SAN DIEGO – Significant increases in adiposity and insulin resistance quickly became apparent in a 12-week study of low-dose antipsychotics to treat mainly nonpsychotic disorders in 144 children.
Newer, “atypical” antipsychotics increasingly are being used to treat mood and disruptive behavior disorders in children, Dr. John W. Newcomer said at the annual meeting of the American Diabetes Association
“It’s a topic of increasing concern in a number of state Medicaid” systems, he said. Concerns have been generated in part by data showing premature mortality in people with mental disorders that’s related primarily to cardiovascular disease but also to cardiometabolic risk.
Children in the open-label study were randomized to flexibly dosed treatment with risperidone, olanzapine, or aripiprazole. It was their first use of antipsychotics.

Dr. John W. Newcomer
    
These were “very low doses,” he emphasized. “These are not doses that would be used to treat a psychotic disorder,” said Dr. Newcomer, who led the study while at Washington University, St. Louis. He now is a professor of psychiatry and behavioral sciences at the University of Miami.
The 5-year Metabolic Effects of Antipsychotics in Children (MEAC) study targeted symptoms of aggression and irritability in patients aged 6-18 years. “Typically, they had been suspended from school,” he said.
The main primary diagnosis was treatment-refractory attention deficit hyperactivity disorder (ADHD) in 57% of patients. “This is what clinicians are using these drugs for in this type of public-sector population – kids who fail two or three courses of stimulants who then are looking for some other treatment.”
Other main diagnoses included oppositional defiant disorder in 22%, pervasive developmental disorder in 6%, bipolar disorder in 4%, and major depression in 3%. Smaller proportions of patients were diagnosed with other mood disorders, Asperger’s syndrome, autism, obsessive-compulsive disorder, or Tourette’s syndrome.
Mean doses were 1 mg/day in the 49 patients on risperidone, 6.3 mg/day in the 46 patients on olanzapine, and 6 mg/day in the 49 patients on aripiprazole. Approximately half of patients also were on stable doses of stimulants for ADHD.
Total body percentage of adiposity increased 2.4% after 12 weeks on antipsychotics – slightly less than a standard deviation, and a highly significant change, Dr. Newcomer and his associates reported. Mean total fat increased 2.3 kg, they added.
The percentage body fat increased the most in the youngest children. Greater changes were seen with olanzapine than with risperidone or aripiprazole. About a fourth of patients on risperidone or aripiprazole showed little change in body fat, but three-quarters on those drugs and nearly all patients on olanzapine showed increases.
Whole-body insulin sensitivity decreased approximately from 8 mg/kg per minute to 7 mg/kg per minute, a significant reduction. Olanzapine produced the greatest reduction in whole-body insulin sensitivity.
Importantly, scores for irritability and aggression improved in all groups, he added.
“I’m not a child psychiatrist. I was not terribly sympathetic to this at the beginning” of clinicians’ use of antipsychotics for these indications, said Dr. Newcomer, who chaired the Drug Utilization Review Board for Missouri Medicaid for 14 years. “But I was educated by the psychiatric outcome. There was really profound psychiatric symptom improvement, with kids going back to school and [behaving differently],” he said. The psychiatric response was similar among treatment groups in the study.
As early as 6 weeks after starting therapy, significant changes could be seen on adiposity. Children with the biggest changes in body fat showed effects within the first month of treatment.
Height, weight, waist circumference, body mass index, and BMI percentile were measured at all visits. At baseline and at 12 weeks, investigators performed dual-energy x-ray absorptiometry (DEXA) scans and MRI to assess changes in adiposity, hyperinsulinemic euglycemic clamp with isotopomers to assess changes in insulin sensitivity, plasma sampling (such as oral glucose tolerance test or measuring fasting glucose and lipids), ECG, and psychiatric ratings. At the 6-week follow-up, patients underwent DEXA, oral glucose tolerance testing, and lab measures of fasting status.
A previous nonrandomized study of 272 antipsychotic-naive children and adolescents reported weight gains of 4-8 kg and increases in BMI percentile for patients taking any of four atypical antipsychotics for a median of 11 weeks, compared with a control group (JAMA 2009;302:1811-2).
The study’s design raised concern that the effects could be larger than reported, however, because overweight or obese children were assigned to drugs considered to have the lowest risk for weight gain, Dr. Newcomer said.
In a post-hoc analysis, Dr. Newcomer showed that at the start of the current study, the children had similar rates of overweight or obesity as did children in the general population, but rates were higher in the cohort by the end of the study. The rate of overweight or obese children in the cohort increased from about 33% to 48%.
“I’m personally skeptical about the idea that it’s the psychiatric disorders themselves that are the metabolic challenge, rather than the treatment being the primary effect,” he said.
Medicaid data suggest that 43% of prescriptions for atypical antipsychotics are for indications that are not backed by evidence justifying use, he said. Visits to U.S. physicians that included prescriptions for antipsychotics to patients aged 20 years or younger more than doubled between 1997 and 2002, to a rate greater than 1,400 per 100,000 visits, a separate study reported (Arch Gen. Psych. 2006;63-681).
The National Institutes of Health funded the study. Dr. Newcomer has been a consultant for or received grants from Janssen Pharmaceuticals Inc., Pfizer Inc. , AstraZeneca, Bristol-Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Schering/Merck, Vivus Inc., Obecure Ltd., Biovail Corp., Lundbeck A/S, Sanofi, and Dainippon Sumitomo Pharma Co. Ltd./Sepracor Inc.
Use Judiciously, Monitor Carefully

We know from a variety of studies in adults using atypical antipsychotics that there is a range of potential weight gain seen with this class of agents. With these agents also being used in children for major mental health concerns, it’s important to have information from studies like Dr. Newcomer’s on the metabolic effects in that age group.
The challenge is finding the balance between selecting the agent that works best for the child and monitoring very carefully for things like rapid weight gain, higher blood glucose values, and issues that may be associated with these metabolic disturbances such as high levels of triglycerides or increases in appetite.

Dr. David M. Kendall
    
Weight gain is part and parcel of our environment, and in many cases is attributed to the availability of calorie-dense foods and decreased physical activity. If we have medications that add to that, in this case the atypical antipsychotics, we have to be judicious about using these medications. Clinicians need to be very attentive, both the in specialty setting and the primary care setting, to watch for changes such as rapid weight gain, and then offer alternative therapies if they are available.
As we’ve learned with adults, anyone who is considering prescribing this class of medications should carefully monitor body weight, plasma glucose (an obvious measure of changing glucose tolerance), and other associated risk factors like blood pressure and blood lipids, which can change as adiposity changes. I think it would be critical to monitor all of those in a situation like this.
Dr. David M. Kendall is chief scientific and medical officer for the American Diabetes Association, Alexandria, Va. He said he has no relevant conflicts of interest.
Enhanced by Zemanta